表紙:アルツハイマー病のバイオマーカーと臨床試験市場:2028年
市場調査レポート
商品コード
1078291

アルツハイマー病のバイオマーカーと臨床試験市場:2028年

Alzheimer's Disease Biomarkers and Clinical Trials Insight 2028

出版日: | 発行: Biomarkers Insights | ページ情報: 英文 900 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.18円
アルツハイマー病のバイオマーカーと臨床試験市場:2028年
出版日: 2022年04月01日
発行: Biomarkers Insights
ページ情報: 英文 900 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
当レポートでは、世界のアルツハイマー病のバイオマーカーと臨床試験市場について調査し、市場の概要とともに、アルツハイマー病の概要と承認済薬剤、新興の治療法、臨床試験動向、および市場に参入する企業の競合情勢などを提供しています。

目次

第1章 世界のアルツハイマー病治療薬市場分析

  • 現在の市場動向
  • 地域別市場シナリオ
  • 将来の市場機会

第2章 承認済アルツハイマー病治療薬:クラス別

  • コリンエステラーゼ阻害剤
  • NMDA受容体作動薬

第3章 アルツハイマー病の新興の治療法

  • モノクローナル抗体
  • 新規NMDA受容体アゴニスト
  • 低分子薬
  • 経口セマグルチド

第4章 アセチルコリンエステラーゼ阻害剤:市場での入手可能性、投与量、特許および価格の洞察

  • ラザダイン
  • ラザダインER
  • アリセプト
  • アリセプトODT
  • レミニル
  • エクセロン
  • シチコリン
  • アルダリティ

第5章 N-メチル-D-アスパラギン酸阻害剤:市場での入手可能性、投与量、特許および価格の洞察

  • ナメンダ
  • ナメンダ XR
  • エビクサ

第6章 治療用抗体:市場での入手可能性、投与量および価格の洞察

  • アデュカヌマブ(アデュヘルム)

第7章 併用薬:市場での入手可能性、投与量および価格の洞察

  • ナムザリック

第8章 アルツハイマー病の承認済ジェネリック医薬品:市場での入手可能性、投与量および価格の洞察

  • ガランタミン
  • ドネペジル
  • リバスチグミン
  • メマンチン
  • エルゴロイドメシレート

第9章 その他の薬剤:市場での入手可能性、投与量および価格の洞察

  • スボレキサント(ベルソムラ)
  • ビタミンE
  • スルブチアミン
  • ピラセタム
  • オリゴマン酸ナトリウム

第10章 世界のアルツハイマー病治療薬の臨床試験の概要

  • バイオ市場別
  • 処方別
  • 組織別
  • 相別
  • 患者セグメント別

第11章 アルツハイマー病の薬剤バイオマーカーの洞察、臨床試験段階別

第12章 市販されているアルツハイマー病の薬剤バイオマーカーの洞察

第13章 競合情勢

  • Allergan
  • Alvogen
  • Dr. Reddy Laboratories
  • Eisai Co Ltd
  • Hoffmann-La Roche Ltd
  • Jassen Pharmaceuticals
  • Lupin
  • Mylan
  • Novartis AG
  • Sun Pharma
  • Teva Pharmaceuticals
図表

List of Figures

  • Figure 1-1: Global - Alzheimer Disease Market Size (US$ Billion), 2020 & 2021
  • Figure 1-2: US vs. ROW - Alzheimer Disease Market (US$ Billion), 2021
  • Figure 1-3: US vs. ROW - Alzheimer Disease Market (%), 2021
  • Figure 1-4: Alzheimer Disease Market Size by Region (US$ Billion), 2021
  • Figure 1-5: Alzheimer Disease Market Size by Region (%), 2021
  • Figure 1-6: Global - Alzheimer Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 1-7: US - Alzheimer Disease Market Size (US$ Billion), 2022 - 2028
  • Figure 2-1: Acetylcholinesterase Inhibitors - Mechanism of Action
  • Figure 2-2: Memantine - Mode of Action
  • Figure 3-1: Designed Monoclonal Antibodies for Alzheimer Disease Discontinued Till Phase-3 Trials
  • Figure 4-1: Razadyne - FDA Approval & First Generic Approval Year
  • Figure 4-2: - Cost of Supply of 60 Tablets & Per Unit Cost of Oral Tablet (US$), March'2022
  • Figure 4-3: Razadyne- Cost of 100ml & Per Unit Cost of 4mg/ml Oral Solution (US$), March'2022
  • Figure 4-4: Razadyne - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 4-5: Razadyne - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-6: Razadyne ER - FDA Approval & First Generic Approval Year
  • Figure 4-7: Razadyne ER - Cost of 30 Capsules & Per Unit Cost of Extended Release Capsule (US$), March'2022
  • Figure 4-8: Razadyne ER - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 4-9: Razadyne ER - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-10: Aricept - FDA Approval Year by Dosage Forms
  • Figure 4-11: Aricept - Approval Year by Region
  • Figure 4-12: US - Aricept Patent Approval & Expiration Year
  • Figure 4-13: US - Aricept FDA Approval & First Generic Approval Year
  • Figure 4-14: Europe - Aricept EMA Approval & First Generic Approval Year
  • Figure 4-15: US - Cost of 30 Tablets & Per Unit Cost of Aricept 5mg Oral Tablets (US$), March'2022
  • Figure 4-16: US - Cost of 30 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (US$), March'2022
  • Figure 4-17: US - Cost of 21 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (US$), March'2022
  • Figure 4-18: US - Cost of 30 Tablets & Per Unit Cost of Aricept 23mg Oral Tablets (US$), March'2022
  • Figure 4-19: UK - Cost of 28 Tablets & Per Unit Cost of Aricept 5mg Oral Tablets (GBP/US$), March'2022
  • Figure 4-20: UK - Cost of 28 Tablets & Per Unit Cost of Aricept 10mg Oral Tablets (GBP/US$), March'2022
  • Figure 4-21: Aricept - Recommended & Incremented Dose for Alzheimer's disease (mg/day)
  • Figure 4-22: Aricept - Time Interval for 1st & 2nd Dose Increment (Weeks)
  • Figure 4-23: Aricept - Recommended Minimum & Maximum Dose (mg/day),
  • Figure 4-24: Aricept ODT - Cost of 30 Tablets & Per Unit Cost of 5mg Oral Tablet (US$), March'2022
  • Figure 4-25: Aricept ODT - Cost of 30 Tablets & Per Unit Cost of 10mg Oral Tablet (US$), March'2022
  • Figure 4-26: Aricept ODT - Recommended Initial & Incremented Dose (mg/day)
  • Figure 4-27: Aricept ODT - Time Interval Required for Dose Increment (Weeks)
  • Figure 4-28: Reminyl - Approval Year by Region
  • Figure 4-29: UK - Cost of 100ml & Per Unit Cost of Reminyl 4mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 4-30: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 8mg Oral Capsules (GBP/US$), March'2022
  • Figure 4-31: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 16mg Oral Capsules (GBP/US$), March'2022
  • Figure 4-32: UK - Cost of 28 Capsules & Per Unit Cost of Reminyl 24mg Oral Capsuless (GBP/US$), March'2022
  • Figure 4-33: Reminyl - Recommended Initial & Incremented Dose (mg/day)
  • Figure 4-34: Exelon - Approval Year by Region
  • Figure 4-35: Exelon - FDA Approval Year by Dosage Forms
  • Figure 4-36: Exelon - FDA Approval & 1st Generic Approval Year
  • Figure 4-37: US - Cost of Supply of 30 Films & Per Unit Cost of Exelon Transdermal Film Extended Release (US$), March'2022
  • Figure 4-38: UK - Cost of Supply of 30 Films & Per Unit Cost of Exelon Transdermal Film Extended Release (GBP/US$), March'2022
  • Figure 4-39: Exelon - Recommended Initial & Incremented Dose (mg/24 Hours)
  • Figure 4-40: India - Cost of Supply of 10 Tablets & Per Unit Cost of Strocit Oral Tablet (INR/US$), March'2022
  • Figure 4-41: India - Cost of Supply of Strocit Injection by Quantity (INR/US$), March'2022
  • Figure 4-42: India - Cost of Supply of 10 Tablets & Per Unit Cost of Clinaxon Oral Tablet (INR/US$), March'2022
  • Figure 4-43: India - Cost of Supply of Clinaxon Injection by Quantity (INR/US$), March'2022
  • Figure 4-44: Citicoline - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 4-45: Aldarity - Recommended Initial & Maximum Dose (mg/day)
  • Figure 5-1: Namenda - Approval Year by Region
  • Figure 5-2: Namenda - FDA Approval Year by Dosage Forms
  • Figure 5-3: Namenda - FDA Approval & First Generic Approval Year
  • Figure 5-4: US - Cost of Supply of 49 Kits & Per Unit Cost of Namenda Oral Kit (US$), March'2022
  • Figure 5-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Namenda Oral Tablets (US$), March'2022
  • Figure 5-6: US - Cost of Supply of 100 Tablets & Per Unit Cost of Namenda Oral Tablets (US$), March'2022
  • Figure 5-7: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Nemdatine 10mg Oral Tablet (GBP/US$), March'2022
  • Figure 5-8: Namenda - Recommended Initial & Incremented Dose (mg/day)
  • Figure 5-9: Namenda - Minimum & Maximum Recommended Dose (mg/day)
  • Figure 5-10: Namenda XR/ Memantine Merz - Approval Year by Region
  • Figure 5-11: Namenda XR - FDA Approval & First Generic Approval Year
  • Figure 5-12: US - Namenda XR Patent Approval & Expiration Year
  • Figure 5-13: US - Cost of Supply of 30 Capsules & Per Unit Cost of Namenda XR Oral Capsules (US$), March'2022
  • Figure 5-14: US - Cost of Supply of 90 Capsules & Per Unit Cost of Namenda XR Oral 14mg & 21mg Capsules (US$), March'2022
  • Figure 5-15: Germany - Cost of 42 Capsules & Per Unit Cost of Memantine Merz 10mg Oral Capsules (Euro/US$), March'2022
  • Figure 5-16: Germany - Cost of 42 Capsules & Per Unit Cost of Memantine Merz 20mg Oral Capsules (Euro/US$), March'2022
  • Figure 5-17: Namenda XR - Recommended Initial & Incremented Dose (mg/day)
  • Figure 5-18: Namenda XR - Minimum & Maximum Recommended Dose (mg/day)
  • Figure 5-19: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Ebixa 10mg Oral Tablet (GBP/US$), March'2022
  • Figure 5-20: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Ebixa 20mg Oral Tablet (GBP/US$), March'2022
  • Figure 6-1: US - Cost of Supply of 1.7ml & Per Unit Price of Aduhelm Intravenous Solution (US$), March'2022
  • Figure 6-2: US - Cost of Supply of 3ml & Per Unit Price of Aduhelm Intravenous Solution (US$), March'2022
  • Figure 6-3: Aduhelm - Recommended Dose by Infusion Cycle (mg/kg)
  • Figure 6-4: Global - Aduhelm Quarterly Sales (US$ Million), Q2 - Q4'2021
  • Figure 7-1: Namzaric - FDA Approval Year by Dose
  • Figure 7-2: US - Namzaric Patent Approval & Expiration Year
  • Figure 7-3: US - Namzaric Patent Issued by Assignees
  • Figure 7-4: Namzaric - Cost of Supply of 30 Capsules & Per Unit Cost of Oral Capsule (US$), March'2022
  • Figure 7-5: Namzaric - Recommended Initial & Incremented Dose Based on Memantine Administration (mg/day)
  • Figure 7-6: Global - Namzaric Quarterly Sales (US$ Million), Q1 & Q2'2021
  • Figure 7-7: Global - Namzaric Quarterly Sales (US$ Million), Q2-Q4'2020
  • Figure 8-1: US - Cost of 30 Capsules & Per Unit Cost of 8mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-2: US - Cost of 30 Capsules & Per Unit Cost of 16mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-3: US - Cost of 30 Capsules & Per Unit Cost of 24mg Galantamine Extended Release Capsule (US$), March'2022
  • Figure 8-4: US - Cost of 100ml & Per Unit Cost of Galantamine 4mg/ml Oral Solution (US$), March'2022
  • Figure 8-5: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 4mg Oral Tablet (US$), March'2022
  • Figure 8-6: US - Cost of Supply of 30 Tablets & Per Unit Cost of Galantamine Oral Tablet (US$), March'2022
  • Figure 8-7: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 8mg Oral Tablet (US$), March'2022
  • Figure 8-8: US - Cost of Supply of 60 Tablets & Per Unit Cost of Galantamine 12mg Oral Tablet (US$), March'2022
  • Figure 8-9: US - Cost of Supply of 60 Galantamine Tablets by Strength (US$), March'2022
  • Figure 8-10: UK - Cost of 100ml & Per Unit Cost of Galantamine 4mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 8-11: Germany - Cost of Supply of 28 Capsules & Per Unit Cost of Galantamine 8mg Oral Capsules (Euro/US$), March'2022
  • Figure 8-12: Germany - Cost of Supply of 28 Capsules & Per Unit Cost of Galantamine 16mg Oral Capsules (US$), March'2022
  • Figure 8-13: Galantamine Tablet & Solution - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-14: Galantamine ER - Recommended Initial Dose & Incremented Dose (mg/day)
  • Figure 8-15: US - Cost of Supply of 30, 90, 100, 500 & 4000 Donepezil 5mg Oral Tablets (US$), March'2022
  • Figure 8-16: US - Cost of Supply of 30, 90, 100, 500 & 2650 Donepezil 10mg Oral Tablets (US$), March'2022
  • Figure 8-17: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 23mg Oral Tablets (US$), March'2022
  • Figure 8-18: US - Cost of 90 Tablets & Per Unit Cost of Donepezil 23mg Oral Tablets (US$), March'2022
  • Figure 8-19: US - Cost of 28 Tablets & Per Unit Cost of Donepezil 5mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-20: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 5mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-21: US - Cost of 28 Tablets & Per Unit Cost of Donepezil 10mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-22: US - Cost of 30 Tablets & Per Unit Cost of Donepezil 10mg Oral Disintegrating Tablets (US$), March'2022
  • Figure 8-23: Germany - Cost of Supply of 28 Tablets & Per Unit Cost of Donepezil 5mg Oral Tablets (Euro/US$), March'2022
  • Figure 8-24: Germany - Cost of Supply of 28 Tablets & Per Unit Cost of Donepezil 10mg Oral Tablets (Euro/US$), March'2022
  • Figure 8-25: Donepezil - Recommended & Incremented Dose for Alzheimer's disease (mg/day)
  • Figure 8-26: Donepezil - Time Interval for 1st & 2nd Dose Increment (Weeks)
  • Figure 8-27: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-28: US - Cost of Supply of 100 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-29: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 1.5mg Oral Capsules (US$), March'2022
  • Figure 8-30: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 3mg Oral Capsules (US$), March'2022
  • Figure 8-31: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 3mg Oral Capsules (US$), March'2022
  • Figure 8-32: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 4.5mg Oral Capsules (US$), March'2022
  • Figure 8-33: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 4.5mg Oral Capsules (US$), March'2022
  • Figure 8-34: US - Cost of Supply of 60 Capsules & Per Unit Cost of Rivastigmine 6mg Oral Capsules (US$), March'2022
  • Figure 8-35: US - Cost of Supply of 500 Capsules & Per Unit Cost of Rivastigmine 6mg Oral Capsules (US$), March'2022
  • Figure 8-36: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 4.6mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-37: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 9.5mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-38: US - Cost of Supply of 30 Films & Per Unit Cost of Rivastigmine 13.3mg/24hr Transdermal Film (US$), March'2022
  • Figure 8-39: UK - Cost of Supply of 28 Rivastigmine Oral Capsules by Strength (GBP/US$), March'2022
  • Figure 8-40: Rivastigmine Oral - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-41: Rivastigmine Patch- Recommended Initial & Incremented Dose (mg/24 Hours)
  • Figure 8-42: US - Cost of Supply of 30 Capsules & Per Unit Cost of Memantine 7mg Oral Capsules (US$), March'2022
  • Figure 8-43: US - Cost of Supply of 100 Capsules & Per Unit Cost of Memantine 7mg Oral Capsules (US$), March'2022
  • Figure 8-44: US - Cost of Supply of 30, 90, & 100 Capsules of Memantine 14mg Oral Capsules (US$), March'2022
  • Figure 8-45: US - Cost of Supply of 30 Capsules & Per Unit Cost of Memantine 21mg Oral Capsules (US$), March'2022
  • Figure 8-46: US - Cost of Supply of 100 Capsules & Per Unit Cost of Memantine 21mg Oral Capsules (US$), March'2022
  • Figure 8-47: US - Cost of Supply of 30, 90, 100 & 500 Capsules of Memantine 28mg Oral Capsules (US$), March'2022
  • Figure 8-48: US - Cost of Supply of 49 Kits & Per Unit Cost of Memantine Kit (US$), March'2022
  • Figure 8-49: US - Cost of Supply of 240ml & Per Unit Cost of Memantine Oral Solution (US$), March'2022
  • Figure 8-50: US - Cost of Supply of 360ml & Per Unit Cost of Memantine Oral Solution (US$), March'2022
  • Figure 8-51: US - Cost of Supply of 50, 60, 100, 500 & 1000 Tablets of Memantine 5mg (US$), March'2022
  • Figure 8-52: US - Cost of Supply of 50, 60, 100, 500, 1000 & 3000 Tablets of Memantine 10mg (US$), March'2022
  • Figure 8-53: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Memantine 10mg Oral Tablets (GBP/US$), March'2022
  • Figure 8-54: UK - Cost of Supply of 28 Tablets & Per Unit Cost of Memantine 20mg Oral Tablets (GBP/US$), March'2022
  • Figure 8-55: UK - Cost of Supply of 100ml & Per Unit Cost of Memantine 10mg/ml Oral Solution (GBP/US$), March'2022
  • Figure 8-56: Memantine Tablet - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-57: Memantine XR - Recommended Initial & Incremented Dose (mg/day)
  • Figure 8-58: US - Cost of Supply of 100 Tablets & Per Unit Price of Ergoloid MesylatesTablet (US$), March'2022
  • Figure 8-59: Ergoloid Mesylates - Daily, Monthly & Annual Treatment Cost (US$), March'2022
  • Figure 9-1: US - Suvorexant Approval Year by Indication
  • Figure 9-2: US - Belsmora Patent 1 Approval & Expiration Year
  • Figure 9-3: US - Belsmora Patent 2 Approval & Expiration Year
  • Figure 9-4: US - Cost of Supply of 30 Tablets & Per Unit Cost of Belsomra Oral Tablets (US$), March'2022
  • Figure 9-5: Belsomra - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-6: Global - Belsomra Annual Sales by Year (US$ Million), 2020 & 2021
  • Figure 9-7: Global - Belsomra Quarterly Sales (US$ Million), 2021
  • Figure 9-8: Global - Belsomra Quarterly Sales (US$ Million), 2020
  • Figure 9-9: UK - Cost of Supply of 100 Vitamin E Tablets by Strength (US$/GBP), March'2022
  • Figure 9-10: Vitamin E - Recommended Minimum & Maximum Dose for Adults (International Units)
  • Figure 9-11: India - Cost of Supply of 10 Tablets & Per Unit Cost of Arcalion Oral Tablet (INR/US$), March'2022
  • Figure 9-12: Sulbutamine - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-13: Sulbutamine - Recommended Minimum & Maximum Tablets (mg/day)
  • Figure 9-14: Sulbutamine - Average Daily, Monthly & Annual Cost of Treatment (US$); March'2022
  • Figure 9-15: UK - Cost of 60 Tablets & Per Unit Cost of Nootropil 1200mg Tablet (GBP/US$), March'2022
  • Figure 9-16: UK - Cost of 90 Tablets & Per Unit Cost of Nootropil 800mg Tablet (GBP/US$), March'2022
  • Figure 9-17: Piracetam - Recommended Minimum & Maximum Dose (mg/day)
  • Figure 9-18: Sodium Oligomannate - Average Number of Capsules Required in Day & Month
  • Figure 9-19: Sodium Oligomannate - Average Daily, Monthly & Annual Cost of Treatment (Yuan/US$), March'2022
  • Figure 10-1: Global - Number of Alzheimer's Drugs in Clinical Trials by Biomarker, 2022 till 2028
  • Figure 10-2: Global - Number of Alzheimer's Drugs in Clinical Trials by Formulation, 2022 till 2028
  • Figure 10-3: Global - Number of Alzheimer's Drugs in Clinical Trials by Organization, 2022 till 2028
  • Figure 10-4: Global - Number of Alzheimer's Drugs in Clinical Trials by Phase, 2022 till 2028
  • Figure 10-5: Global - Number of Alzheimer's Drugs in Clinical Trials by Patient Segment, 2022 till 2028
目次

“Alzheimer's Disease Biomarkers and Clinical Trials Insight 2028” Report Highlights:

  • Global Alzheimer's Disease Antibodies Market Opportunity: > USD 5 Billion
  • Alzheimer's Disease Clinical Trials Insight: > 200 Drugs In Trials
  • Alzheimer's Disease Biomarkers Sourced During Clinical Trials
  • Alzheimer's Disease Insight By Classification
  • Insight On Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

With the rapid ageing of world's population, there is significant rise in the prevalence of dementia associated with Alzheimer disease. The prevalence of Alzheimer disease has become a major social issue as it affects the length and quality of patient's life and the physiological and economic status of patients and their families. Presently available Alzheimer disease drugs have been unable to halt the progression of Alzheimer disease. Therefore, researchers believed that early diagnosis and prevention of Alzheimer disease is of utmost important to reduce severity and enhance prognosis of the disease.

Therefore, the search for potential clinical biomarkers in Alzheimer disease is one of the hottest areas of research among scientists. The biomarkers identified should be specific, suitable for routine use in clinical practice, and indicate specific stages of the disease. Currently, the most-cited blood and CSF biomarkers for diagnosing Alzheimer disease include the 42-amino acid form of amyloid-beta peptide (Ab1-42), the Ab1-42/Ab1-40 ratio, total and phosphorylated fractions of tau proteins (T-Tau and P-Tau, respectively), neurofilament light chain (NFL) protein, phosphorylated tau at position threonine 181 (P-Tau 181), and 217 (P-Tau217). Apart from this, several ongoing clinical studies are also evaluating other potential biomarkers which can aid in development of diagnostic test or novel targeted therapy for Alzheimer disease.

Recently researchers at Mayo Clinic have identified a new set of markers in blood plasma. This discovery could lead to the development of improved diagnostic tests for Alzheimer's disease. The study focuses on the RNA molecules which are present in plasma as potential biomarkers for the Alzheimer's disease in African Americans. The study builds on previous research that identified genetic risk factors for Alzheimer's disease and established that RNA molecules in blood plasma could potentially be used as biomarkers. This research demonstrates that this discovery could lead to more accurate Alzheimer's disease screening for everyone, particularly for the people and communities at greatest risk.

Traditionally, the detection of disease-causing pathology associated with Alzheimer's disease and Vascular Contributions to Cognitive Impairment and Dementia (VCID) is limited to cognitive evaluations and neuroimaging like MRI and PET scans. To mitigate the challenges associated with conventional detection methods, researchers have identified several blood biomarkers, which can be beneficial in the diagnosis of Alzheimer's and other dementias. The study demonstrated that higher pTau181 and lower beta-amyloid in the blood indicate amyloid plaques of Alzheimer's in the brain. Further, researchers also found that inflammation proteins in blood were related to damage to blood vessels in the brain. It is suggested that advancements in research regarding biomarkers will allow physicians to detect changes in brain, monitor the disease's progression, and test the effectiveness of potential treatments.

As per our report findings, the global Alzheimer disease drug market is expected to surpass US$ 5 Billion by 2028 which is mainly attributed to the rise in prevalence of Alzheimer disease. US is expected to hold a dominant share in the global market over the forecast period, owing to rising government initiatives for management of Alzheimer disease, rising awareness among population for early diagnosis of disease, and presence of strong research and development sector. Moreover the rising focus of market players in business strategies such as acquisitions, partnerships, and others are expected to fuel the growth of Alzheimer disease biomarkers market over the forecast period.

The report provides in-depth analysis on more than 100 biomarkers which are present in clinical trials across various drugs for Alzheimer disease. The report presents detailed analyses of the key market trends, drivers and opportunities, market size and forecasts, top investment pockets, and competitive landscape. Strategies recorded by the key players are analyzed thoroughly to understand the competitive outlook of the market.

Table of Contents

1. Global Alzheimer Drug Market Analysis

  • 1.1 Current Market Trends
  • 1.2 Regional Market Scenario
  • 1.3 Future Market Opportunity

2. Approved Alzheimer's Disease Drugs by Class

  • 2.1 Cholinesterase Inhibitors
  • 2.2 NMDA Receptor Agonist

3. New Emerging Therapies in Alzheimer's Disease

  • 3.1 Monoclonal Antibody
  • 3.2 Novel NMDA Receptor Agonists
  • 3.3 Small Molecules Drug
  • 3.4 Oral Semaglutide

4. Acetylcholinesterases Inhibitor: Market Availability, Dosage, Patent & Price Insight

  • 4.1 Razadyne
  • 4.2 Razadyne ER
  • 4.3 Aricept
  • 4.4 Aricept ODT
  • 4.5 Reminyl
  • 4.6 Exelon
  • 4.7 Citicoline
  • 4.8 Aldarity

5. N-methyl-D-aspartate Inhibitors: Market Availability, Dosage, Patent & Price Insight

  • 5.1 Namenda
  • 5.2 Namenda XR
  • 5.3 Ebixa

6. Therapeutic Antibodies: Market Availability, Dosage & Price Insight

  • 6.1 Aducanumab (Aduhelm)

7. Combinational Drugs: Market Availability, Dosage & Price Insight

  • 7.1 Namzaric

8. Approved Generic Drugs for Alzheimer's: Market Availability, Dosage & Price Insight

  • 8.1 Galantamine
  • 8.2 Donepezil
  • 8.3 Rivastigmine
  • 8.4 Memantine
  • 8.5 Ergoloid Mesylates

9. Other Drugs: Market Availability, Dosage & Price Insight

  • 9.1 Suvorexant (Belsomra)
  • 9.2 Vitamin E
  • 9.3 Sulbutiamine
  • 9.4 Piracetam
  • 9.5 Sodium Oligomannate

10. Global Alzheimer's Disease Drugs Clinical Trials Overview

  • 10.1 By Biomarket
  • 10.2 By Formulation
  • 10.3 By Organization
  • 10.4 By Phase
  • 10.5 By Patient Segment

11. Alzheimer's Drug Biomarker Insight By Clinical Trials Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Clinical
  • 11.4 Phase-I
  • 11.5 Phase-I/II
  • 11.6 Phase-II
  • 11.7 Phase-II/III
  • 11.8 Phase-III
  • 11.9 Preregistration
  • 11.10 Registered

12. Marketed Alzheimer's Drug Biomarker Insight

13. Competitive Landscape

  • 13.1 Allergan
  • 13.2 Alvogen
  • 13.3 Dr. Reddy Laboratories
  • 13.4 Eisai Co Ltd
  • 13.5 Hoffmann- La Roche Ltd
  • 13.6 Jassen Pharmaceuticals
  • 13.7 Lupin
  • 13.8 Mylan
  • 13.9 Novartis AG
  • 13.10 Sun Pharma
  • 13.11 Teva Pharmaceuticals